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cytes during anti-T lymphocyte therapy might define a sub-
group of transplant recipients at risk for PrLD. Monitoring the 
percentage of CD19+ lymphocytes during anti-T cell therapy 
allowed early modification of the immunosuppressive and anti-
viral regimen. apparently with favorable alteration in the lym-
phoproliferative process. This preliminary experience suggests 
that reduction in overall immunosuppression with concomitant 
initiation of antiviral therapy for patients with elevated levels 
of circulating CD19+ B lymphocytes may positively impact the 
natural history of PJ'LD. Although more extensive evaluation, 
including larger clinical trials, must validate our findings, pe-
ripheral B lymphocyte analysis using mAb and flow cytometry 
may represent an effective screening strategy . 
of patients at risk for PJ'LD. 
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In contrast to kidney and heart. liver transplantation does 
not seem to benefit from HLA-matching in most patients. 
Furthermore. lower graft survival rates have been reported 
when HLA compatibility between donor and recipient is 
present (]-5l. Since HLA mismatching contributes to liver 
allograft rejection, we have proposed a dualistic role of HLA 
in liver transplantation (ll. HLA-matching reduces acute 
cellular rejection but augments other immunologic mecha· 
nisms of allograft injury, especially those mediated by major 
histocompatibility complex (MHCl*-restricted lymphocytes. 
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• AbbreVIations: CMV. cytomegalovirus: HBV. hepatitis B virus. 
HCB. hepatitis C virus: MHC. major histocompatibility complex: 
OLTx. orthotopIC liver transplantation. 
In support of this concept, we have recently reported a higher 
incidence of CMV hepatitis in HLA-DR matched liver trans-
plants. which was also associated with a higher frequency 
and earlier onset of chronic rejection (6l. 
Hepatitis Band C virus (HBV. HCV) infections are a major 
cause of end-stage liver disease requiring liver transplanta-
tion. However. both viruses are difficult to eradicate, ensur-
ing that the viral infection will persist and that recurrent 
hepatitis will occur in many reCipIents (7. 8). In the present 
study we investigated whether HLA matching affects the 
recurrence of HBV and HCV hepatltls after liver transplan-
tation, 
From January 1991 to July 1992,98 adult patients under-
went orthotopic liver transplantatIOn (OLTxl because end-
stage liver disease secondary to HBV and/or HCV infections. 
Of these. 9 (9%) died during the first month after OLTX. The 
remaining 89 patients constituted the study group. Thirty-
one patients (35%) had hepatitis B. 53 (59%) had hepatitis C. 
and 5 (6%) had Band C hepatitis. All hepatitis B patients 
---------.-..• --... -- .. ~ .. -. ----------~ ._-- ... -
February 27. 1995 BRIEF COMMUNICATIONS 641 
were HBsAg-positive and HBV DNA-negative before trans-
plantation. HBeAg was available for 23 patients. and 17 of 
them (74%) tested positive. Hepatitis C diagnosis was per-
fonned by the presence of anti-HCV antibodies in the serum 
by a first-generation ELISA (Abbot Laboratories. Abbot 
Park. IL) and HCV RNA detection in the original liver by 
reverse transcriptase polymerase chain reaction (PCR)' HLA 
typing of patients and donors was done by standard serolog-
ical techniques based on lymphocytotoxicity testing with sera 
against HLA-A. B. DR. and DQ antigens. 
Primary immunosuppression included in all patients ta-
crolimus (FK506) and steroids. Tacrolimus was initially 
given in a continuous infusion at 0.1 mg/kg!day, which was 
converted to an oral dose of 0.15 mg/kg!day every 12 hr with 
the return of bowel function. Subsequent dosage adjustments 
were guided by the quality of the graft, the presence of 
rejection, toxicity, and tacrolimus plasma trough level (nor-
mal value: <2 ng!ml). Rejection episodes were treated with a 
1-g pulse of methylprednisolone or a 5-day taper of high-dose 
steroids from 200 to 20 mg. Steroid-resistant rejection epi-
sodes were treated with a 5-day course of OKT3. 
During a follow-up of between 18 and 24 months. 45 of the 
89 (51%) liver transplant recipients had recurrence ofhepa-
titis at (mean:!: sm 259:!: 174 days after transplantation. Re-
currence of hepatitis was defined by the presence of portal 
and parenchymal mononuclear infiltration and isolated hep-
atocyte necrosis, as evidenced by acidophilic bodies in his-
topathology. In addition, diagnosis hepatitis B recurrence 
required the expression of HBsAg and HBcAg by liver cells. 
detennined by immunoperoxidase techniques. along with 
positive HBsAg in the serum. The diagnosis of hepatitis C 
recurrence required the presence of anti-HCV antibodies by a 
second-generation ELISA (Abbot Laboratories. Abbot Park. 
ILl. and detection of HCV RNA in the liver biopsy. In 13 of 
the 31 patients with recurrent hepatitis C, HCV RNA was 
also investigated in serum specimens. and all them were 
positive. Other causes of liver dysfunction. such as rejection, 
drug toxicity, or viral infections by the herpesvirus group 
ICMV. EBV and herpes simplex). were excluded. 
Fourteen of 31 patients (45%) with HBV infection-27 of 53 
151'7r) with HCV and 4 of 5 (80%) with HBV and HCV infec-
tions- had recurrent hepatitis. The incidence of recurrence 
of hepatitis was significantly higher for HLA-B-compatible 
liver transplants recipients. Nineteen of the 45 patients 
(42'7<:) with recurrent hepatitis shared at least one HLA-B 
antigen with the donor. In contrast. HLA-B sharing was 
found in 9 of 44 patients (20O/rl without recurrent hepatitis 
I P<O.051. One or two HLA-B antigen matching increased the 
relative risk (Odds ratio) of recurrent hepatitis 2.8 times. 
There seemed to be no preferential sharing of any particular 
HLA-B antigen in the recurrent hepatitis group. There were 
no differences between HLA-B-matched and -unmatched pa-
tients In tenns of severity of recurrent hepatitis. No signifi-
cant associations were found between recurrence of hepatitis 
and donor-recipient sharing of HLA-A. HLA-DR. and 
HLA-DQ antigens. Kaplan-Meier analysis showed that 
HLA-B matching significantly increased the probability of 
developing recurrent hepatitis from 40'7c to 75,} at two years 
in patients with HBV infection (patients with HBV and HCV 
infection are included in this grOUP) (Fig. lAl, and from 39% 
to 76% in patients with HCV infection (Fig. 1Bl. 
These observations suggest that HLA-B sharing between 
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FIGURE 1. The probability of developing hepatitis recurrence in 
HLA-B-matched and -unmatched liver transplant recipients with 
HBV (A) and HCV (8) infection. 
donor and recipient promotes the recurrence of HBV and 
HCV hepatitis in liver transplant recipients. Our results 
confinn previous studies showing that HLA class I matching 
between donor and recipient is associated with the develop-
ment of hepatic lesions in recurrent HBV infection after liver 
transplantation (91. Infection of the liver allograft by HBV 
and HCV is a frequent event in liver transplant recipients 
who are HBV or HCV carriers. However. a dissociation be-
tween the virus load and replication and the severity of 
hepatic lesions has been observed in liver transplant recipi-
ents (10. 1 J). This occurs even in the presence of increasing 
VIral titers after liver transplantation (12). These observa-
tions are similar to the existence of an HBV or HeV carrier 
state for many years without evidence of liver damage U31. 
Both suggest that the viruses are not cytopathic by them-
selves and that immune-mediated mechanisms are the most 
important factor in liver injury. 
Our results suggest that MHC restriction of antigen-spe-
cific lymphocyte reactivity might be involved in the allograft 
damage by HBV and HCB. It has been shown that HBV and 
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HCV infections increase the expression of HLA class I anti-
gens on hepatocytes surface U4, 15). Although exogenous 
antigens and viral particles are in general associated with a 
class II MHC-restricted response, there is evidence that 
HBV and HCV are among the few antigens presented in 
association with class I molecules (16). Thus, liver-infiltrat-
ing HBV and HCV specific lymphocytes might be HLA class 
I-restricted (17, 18). Infection of a transplanted liver by HBV 
or HCV leads to the expression of viral antigens, which-in 
context with MHC class I molecules on the cell surface-
could be recognized by recipient T lymphocytes. HLA match-
ing would permit a more efficient MHC-restricted antigen 
presentation, thereby augmenting cell-mediated immune re-
sponses toward HBV- and HCV-infected liver allografts. 
Thus, theoretically immunosuppressive therapy should re-
duce liver injury mediated by immune mechanisms (19). 
However, it also increases virus replication, which may be 
associated with an increased antigen expression and greater 
spread through the allografted liver. 
In summary, the findings described in this report provide 
further support for the concept of a dualistic role of HLA in 
liver transplantation, and help to explain why survival is 
poorer with better matches. Although HLA matching reduces 
acute cellular rejection, it increases the risk of CMV hepatitis 
and recurrence of HBV and HCV hepatitis. A better under-
standing of all these different HLA-associated immune mech-
anisms may lead to improved management strategies in he-
patic transplantation. 
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